2025-05-01 18:24:30
Latest Post
Monarch Networth Capital IFSC Pvt. Ltd. receives Registered Fund Management Entity (Retail) License from IFSCA, GIFT City
Lucent Industries Ltd enters into partnership agreement with Clusterdev Technologies Pvt Ltd
South Indian Bank hosts Season 1 of National Co-lending Summit - SEED
Inox Green signs agreement for O&M of 675 MWp of solar projects
Union Bank of India Launches MSME & CASA Outreach Programs to pass on benefits of back to back RBI-MPC rate cuts and Deepen Customer Engagement
Stock Report
Glenmark Life Sciences Ltd posts net profit of Rs. 95.31 crores in Q2 FY2025
Posted On : 2024-10-25 19:45:16( TIMEZONE : IST )
Glenmark Life Sciences Ltd has reported Standalone financial results for the period ended September 30, 2024.
Financial Results (Q2 FY2025) - QoQ Comparison
The company has reported total income of Rs. 515.412 crores during the period ended September 30, 2024 as compared to Rs. 594.109 crores during the period ended June 30, 2024.
The company has posted net profit / (loss) of Rs. 95.316 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs. 111.483 crores for the period ended June 30, 2024.
The company has reported EPS of Rs. 7.75 for the period ended September 30, 2024 as compared to Rs. 9.08 for the period ended June 30, 2024.
| Financials | Q2 FY2025 | Q1 FY2025 | % Change |
| Total Income | ₹ 515.412 crs | ₹594.109 crs |  -13.25% |
| Net Profit | ₹95.316 crs | ₹111.483 crs | -14.50% |
| EPS | ₹7.75 | ₹9.08 | -14.65% |
Financial Results (Q2 FY2025) - YoY Comparison
The company has reported total income of Rs. 515.412 crores during the period ended September 30, 2024 as compared to Rs.600.732 crores during the period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.95.316 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs.118.737 crores for the period ended September 30, 2023.
The company has reported EPS of Rs.7.75 for the period ended September 30, 2024 as compared to Rs.9.69 for the period ended September 30, 2023.
| Financials | Q2 FY2025 | Q2 FY2024 | % Change |
| Total Income | ₹ 515.412 crs | ₹600.732 crs | -14.20% |
| Net Profit | ₹95.316 crs | ₹118.737 crs | -19.73% |
| EPS | ₹7.75 | ₹9.69 | -20.02% |
Financial Results (Half Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.1109.521 crores during the 6 Months period ended September 30, 2024 as compared to Rs.1181.033 crores during the 6 Months period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.206.799 crores for the 6 Months period ended September 30, 2024 as against net profit / (loss) of Rs.254.187 crores for the 6 Months period ended September 30, 2023.
The company has reported EPS of Rs.16.83 for the 6 Months period ended September 30, 2024 as compared to Rs.20.75 for the 6 Months period ended September 30, 2023.
| Financials | Half Year Ended FY2025 | Half Year Ended FY2024 | % Change |
| Total Income | ₹1109.521 crs | ₹1181.033 crs | -6.06% |
| Net Profit | ₹206.799 crs | ₹254.187 crs | -18.64% |
| EPS | ₹16.83 | ₹20.75 | -18.89% |
Shares of Glenmark Life Sciences Ltd was last trading in BSE at Rs. 1039.40 as compared to the previous close of Rs. 1073.35. The total number of shares traded during the day was 4684 in over 607 trades.
The stock hit an intraday high of Rs. 1097.75 and intraday low of 1034.50. The net turnover during the day was Rs. 4935702.00.
